No connection

Search Results

TNON

BEARISH
$0.8 Live
Tenon Medical, Inc. · NASDAQ
Target $2.75 (+244.6%)
$0.64 52W Range $2.48
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 21, 2026
Market cap
$9.01M
P/E
N/A
ROE
-228.1%
Profit margin
N/A
Debt/Equity
0.03
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
90%
TNON exhibits critical financial fragility with a Piotroski F-Score of 1/9, signaling severe weakness in profitability and operational efficiency. While the company shows impressive top-line momentum with 92.3% YoY revenue growth and maintains a low debt profile, these are overshadowed by a catastrophic -193.52% operating margin and a -228.06% ROE. The long-term price performance is devastating, with a near 100% loss over 5 years, suggesting a failed historical value proposition. Despite optimistic analyst price targets, the deterministic health metrics indicate a high risk of continued equity erosion.

Key Strengths

Strong YoY revenue growth of 92.30%
High gross margin of 59.79% indicating product value
Very low leverage with a Debt/Equity ratio of 0.03
Healthy short-term liquidity (Current Ratio 2.11)
Improving EPS trend (less negative over the last 4 quarters)

Key Risks

Critical financial health as evidenced by Piotroski F-Score of 1/9
Severe operational losses with an operating margin of -193.52%
Extreme equity erosion indicated by ROE of -228.06%
Catastrophic long-term price performance (5Y change -100%)
Micro-cap status leading to high volatility and liquidity risk
AI Fair Value Estimate
Based on comprehensive analysis
$0.55
-31.1% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
22
Weak
Value
30
Future
55
Past
10
Health
15
Dividend
0
AI Verdict
High-Risk Speculative
Key drivers: Extreme revenue growth vs. extreme operational losses, Critical failure in deterministic health scores, Total collapse of long-term shareholder value
Confidence
85%
Value
30/100

Trades at a premium to book value despite negative earnings.

Positives
  • Relatively low Price/Sales ratio (2.29)
Watchpoints
  • High Price/Book ratio (4.41) for a non-profitable entity
  • No Graham Number available due to lack of earnings
Future
55/100

Growth is strong, but sustainability is questionable without margin improvement.

Positives
  • Rapid revenue expansion (92%+)
  • EPS is trending toward zero (reducing losses)
Watchpoints
  • High cash burn rate
  • Unproven path to net profitability
Past
10/100

Historical price action indicates a total loss of capital for long-term holders.

Positives
No standout positives identified.
Watchpoints
  • 5-year return of -100%
  • 3-year return of -99.5%
Health
15/100

Liquidity is currently stable, but fundamental financial health is critical.

Positives
  • Low Debt/Equity
  • Strong Current Ratio
Watchpoints
  • Piotroski F-Score of 1/9
  • Negative ROA and ROE
Dividend
0/100

Company is in a growth/survival phase; no capital return to shareholders.

Positives
No standout positives identified.
Watchpoints
  • No dividend history
  • 0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$0.8
Analyst Target
$2.75
Upside/Downside
+244.6%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for TNON and closest competitors.

Updated 2026-04-20
TNO
Tenon Medical, Inc.
Primary
5Y
-100.0%
3Y
-99.5%
1Y
-28.8%
6M
-37.7%
1M
-0.6%
1W
-2.7%
NOT
Inotiv, Inc.
Peer
5Y
-98.8%
3Y
-95.0%
1Y
-84.2%
6M
-82.6%
1M
-31.9%
1W
-2.0%
SIL
Silo Pharma, Inc.
Peer
5Y
-96.0%
3Y
-78.0%
1Y
-52.1%
6M
-8.0%
1M
+60.9%
1W
+16.8%
GEL
Gelteq Limited
Peer
5Y
-73.9%
3Y
-73.9%
1Y
-14.8%
6M
-43.5%
1M
+3.7%
1W
+13.2%
IMR
Immuron Limited
Peer
5Y
-85.9%
3Y
-59.6%
1Y
-51.9%
6M
-61.7%
1M
-3.3%
1W
-1.0%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-1.28
PEG Ratio
N/A
P/B Ratio
4.41
P/S Ratio
2.29
EV/Revenue
2.15
EV/EBITDA
-0.72
Market Cap
$9.01M

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin -193.52%
Gross Margin 59.79%
ROE -228.06%
ROA -72.88%

Growth

Revenue and earnings growth rates

Revenue Growth +92.3%
Earnings Growth N/A
Q/Q Revenue Growth +92.34%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.03
Low debt
Current Ratio
2.11
Strong
Quick Ratio
1.7
Excellent
Cash/Share
$0.33

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
68.7%
Op. Margin
-193.5%
Net Margin
-191.2%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
1.13x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
109%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-12
$N/A
2026-03-19
$-0.22
+38.9% surprise
2025-11-13
$-0.4
-8.1% surprise
2025-08-13
$-0.36
+23.4% surprise

Healthcare Sector Comparison

Comparing TNON against 498 companies in the Healthcare sector (28 bullish, 153 neutral, 317 bearish)
Return on Equity (ROE)
-228.06%
This Stock
vs
-95.47%
Sector Avg
+138.9% (Excellent)
Debt to Equity
0.03
This Stock
vs
2.89
Sector Avg
-99.0% (Less Debt)
Revenue Growth
92.3%
This Stock
vs
137.48%
Sector Avg
-32.9% (Slower)
Current Ratio
2.11
This Stock
vs
4.66
Sector Avg
-54.8% (Weaker)

Similar Companies

Peer comparison within the same industry

TNON Tenon Medical, Inc.
BEARISH
Mkt Cap
$9M
P/E
-
ROE
-228.1%
Price
$0.8
NOTV Inotiv, Inc.
BEARISH
Mkt Cap
$8M
P/E
-
ROE
-49.8%
Price
$0.24
 Compare with TNON
SILO Silo Pharma, Inc.
BEARISH
Mkt Cap
$8M
P/E
-
ROE
-74.6%
Price
$0.52
 Compare with TNON
GELS Gelteq Limited
BEARISH
Mkt Cap
$8M
P/E
-
ROE
-43.0%
Price
$0.77
 Compare with TNON
IMRN Immuron Limited
BEARISH
Mkt Cap
$8M
P/E
-
ROE
-39.7%
Price
$0.79
 Compare with TNON

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

WILLIAMSON KEVIN
Chief Financial Officer
Stock Award
2026-03-03
1,041 shares
FERRARI RICHARD M
Director
Stock Award
2025-12-31
64,478 shares
WEIGLE ROBERT K.
Director
Stock Award
2025-12-31
10,732 shares
HOCHSCHULER STEPHEN H
Director
Stock Award
2025-12-31
10,732 shares
FOSTER STEVEN M
Chief Executive Officer
Stock Award
2025-12-31
140,936 shares
HOWARD IVAN
Director
Stock Award
2025-12-31
10,732 shares
GINN RICHARD
Chief Technology Officer
Stock Award
2025-12-31
126,577 shares
JACQUES KRISTINE M
Director
Stock Award
2025-12-31
10,729 shares
WILLIAMSON KEVIN
Chief Financial Officer
Stock Award
2025-12-31
58,987 shares
FOSTER STEVEN M
Chief Executive Officer
Buy
2025-11-14
19,455 shares · $22,957
GEIST WYATT D.
Officer
Buy
2025-11-14
19,455 shares · $22,957
GRAWEY NATHANIEL A.
Officer
Buy
2025-11-14
101,167 shares · $119,377
Insider transactions can signal confidence or concerns about company prospects

Past News Coverage

Recent headlines mentioning TNON from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile